Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mexiletine as a treatment for primary erythromelalgia: normalization of biophysical properties of mutant L858F NaV 1.7 sodium channels.

British journal of pharmacology - 1 Oct 2014

Cregg R, Cox J J, Bennett D L H, Wood J N, Werdehausen R

Abstract excerpt

BACKGROUND AND PURPOSE: The non-selective sodium channel inhibitor mexiletine has been found to be effective in several animal models of chronic pain and has become popular in the clinical setting as an orally available alternative to lidocaine. It remains unclear why patients with monogenic pain disorders secondary to gain-of-function SCN9a mutations benefit from a low systemic concentration of mexiletine, which...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Analgesics
Share to Erythromelalgia

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to HEK293 Cells

Share to Ion Channel Gating

Share to Mutagenesis, Site-Directed

Share to NAV1.7 Voltage-Gated Sodium Channel

Share to Patch-Clamp Techniques

Share to Sodium Channel Blockers

Source

Open in PubMed Open full text

Identifiers

PMID: 24866741
DOI: 10.1111/bph.12788
PMCID: PMC4209151

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mexiletine as a treatment for primary erythromelalgia: normalization of biophysical properties of mutant L858F NaV 1.7 sodium channels.PMID 24866741Read ↗

Novel mutations mapping to the fourth sodium channel domain of Nav1.7 result in variable clinical manifestations of primary erythromelalgia.Semantic proximity Read ↗

NaV1.7 gain-of-function mutations as a continuum: A1632E displays physiological changes associated with erythromelalgia and paroxysmal extreme pain disorder mutations and produces symptoms of both disorders.Semantic proximity Read ↗

Mexiletine-responsive erythromelalgia due to a new Na(v)1.7 mutation showing use-dependent current fall-off.Semantic proximity Read ↗

Towards development of Nav1.7 channel modulators for pain treatment: A comparison of mexiletine effect in two cell models by automated patch clampSemantic proximity Read ↗

Stem cell-derived sensory neurons modelling inherited erythromelalgia: normalization of excitability.Semantic proximity Read ↗

Pain disorders and erythromelalgia caused by voltage-gated sodium channel mutations.Semantic proximity Read ↗

Erythromelalgia mutation L823R shifts activation and inactivation of threshold sodium channel Nav1.7 to hyperpolarized potentials.Semantic proximity Read ↗

Na(V)1.7 mutant A863P in erythromelalgia: effects of altered activation and steady-state inactivation on excitability of nociceptive dorsal root ganglion neurons.Semantic proximity Read ↗

Novel SCN9A mutations underlying extreme pain phenotypes: unexpected electrophysiological and clinical phenotype correlations.Semantic proximity Read ↗

Gain-of-function mutation in Nav1.7 in familial erythromelalgia induces bursting of sensory neurons.Semantic proximity Read ↗

Effects of temperature and mexiletine on the F1473S Na+ channel mutation causing paramyotonia congenita.Semantic proximity Read ↗

Nonlinear effects of hyperpolarizing shifts in activation of mutant Nav1.7 channels on resting membrane potential.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.